Phase 2 N=140 Polypill in Acute Coronary Syndrome
Acute Coronary Syndrome · Lipid Disorder · Coronary Artery Disease
Primary: Low Density Lipoprotein - Cholesterol — -6.74; 0.53 mg/dL — p=0.27
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=64 Post Acute Coronary Event Smoking Study
Smoking Cessation · Acute Coronary Syndrome
Primary: Smoking Cessation: 7 Day Point Prevalence Abstinence — 0.46; 0.44 proportion of participants
Phase 2 N=8 Healthy Heart Habits
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale
Phase 4 N=100 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
Acute Coronary Syndrome
Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…
Phase 2 N=547 Safety Study of Apixaban in Recent Acute Coronary Syndrome
Acute Coronary Syndrome (ACS)
Primary: Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or…
Phase 2 N=60 Evolocumab in Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Percent Change in LDL-Cholesterol — -68.78; -27.58 percent change
Phase 3 N=9,326 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Acute Coronary Syndrome
Primary: Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke — 10.06; 24.64; 10.96; 24.13 percentage of…
Phase 3 N=18,226 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121
N/A N=254 PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE
Stroke, Ischemic · Acute Coronary Syndrome
Primary: Presence of Myocardial Infarction — 126; 121 Participants
N/A N=169 Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
Phase 4 N=204 Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Acute Coronary Syndrome (ACS)
Primary: Mean Change From Baseline to Week 4 in P2Y12 Reaction Units During Period 1 — -18.2 P2Y12 reaction unit
N/A N=130 Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
Acute Coronary Syndrome (ACS)
Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale
Phase 2 N=100 Evolocumab in Patients With Acute MI
Acute Coronary Syndrome
Primary: Change in LDL-Cholesterol — -70.59; -44.78 percent change mg/dL — p=.0001
Phase 3 N=2,198 European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
Acute Coronary Syndrome
Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=47 Positive Psychology for Acute Coronary Syndrome Patients
ACS - Acute Coronary Syndrome
Primary: Feasibility of the PP-MI Based Health Behavior Intervention — 10.0 exercises completed
N/A N=12,227 Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Percentage of Participants With Major Adverse Cardiovascular Events (MACE) — 13.14; 17.12 percentage of participants — p=0.7108
Phase 3 N=15,526 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
Acute Coronary Syndrome · Myocardial Infarction · Myocardial Ischemia
Primary: The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke — 7.4; 6.1; 6.1 Percentage of patients — p=0.020
N/A N=253 Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization
Acute Coronary Syndrome
Primary: Adherence to Cardioprotective Medications (Clopidogrel, Statins, Beta Blockers, ACE-inhibitor/ARB) — 89.3; 73.9 percentage of participants — p=0.003
N/A N=871 Risk Markers in the Acute Coronary Syndromes
Chest Pain · Coronary Artery Disease · Unstable Angina Pectoris
Primary: Total Mortality. — 138 Participants.
Phase 2 N=150 Comparison of Depression Interventions After Acute Coronary Syndrome
Acute Coronary Syndrome · Depression
Primary: Depressive Symptom Reduction — -6.6; -10.1 Scores on a scale — p=0.01
Phase 2 N=282 Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
Acute Coronary Syndrome
Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD) — 57.86; 35.61; 53.92 PRU — p=0.188
N/A N=641 Acute Coronary Syndrome KCMC
Acute Coronary Syndrome
Primary: Acceptability as Measured by the Acceptability of Intervention Measure (AIM) — 4.82 score on a scale
Phase 3 N=719 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours…
N/A N=105 Evaluating Increasing Physical Activity After Acute Coronary Syndrome
Physical Activity · Acute Coronary Syndrome
Primary: Change in Mean Daily Steps — 264; 1501 Steps
N/A N=3,691 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
Coronary Artery Diseases
Primary: 30-day Composite Major Adverse Cardiac Event (MACE) — 256; 83 participants
Phase 3 N=300 A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
Coronary Heart Disease
Primary: Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment — 43.8; 10.1 Percentage raise in HDL-C Levels
N/A N=769 Early Discharge After Primary Percutaneous Coronary Intervention
ST Elevation Myocardial Infarction
Primary: All Cause Mortality and Readmission at 30 Days. — 16; 28 participants — p=<0.05
Phase 3 N=15,871 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Coronary Heart Disease
Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup